Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nilotinib treatment-free remission in chronic phase chronic myeloid leukemia after sustained MR4.5
NL-OMON38513Phase 2Withdrawn
- Sponsor
- Novartis
- Start
- May 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nilotinib in chronic myelogenous leukemia (CML), sponsored by Novartis. Primary endpoint: Major molecular response at 48 weeks after start of treatment-free remission phase. Planned start May 2013; status: withdrawn.
02
Drugs
nilotinib
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on NL-OMON38513.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38513.